Publications - Bright Peak Therapeutics

November 9, 2024

Poster presentation SITC Annual Meeting 2024, Houston

Identification of PD1-IL2(TAP) – a PD-1 Blocking Immunoconjugate Harboring a Tumor-Activatable Masked IL-2 Payload Lacking Binding to IL2Rbeta/CD122

April 9, 2024

Poster presentation AACR Annual Meeting 2024, San Diego

The first-in-class PD1-IL18 conjugate BPT567 induces potent anti-tumor immunity by preferentially activating PD1+IL18R+ intratumoral effector T cells in cis

April 17, 2023

Poster presentation AACR Annual Meeting 2023, Orlando

A First-in-Class PD1-IL18 Immunocytokine (BPT567) Targets PD-1+ IL18R+ CD8+ T Effector Cells Enriched in the Tumor Microenvironment and Exhibits Potent Antitumor Efficacy With Excellent Tolerability

February 3, 2023

Poster presentation, selected flash talk and prize winner at the 3rd Swiss Cytometry Meeting, Zürich

An algorithm-aided flow cytometry data analysis pipeline to analyze non-human primate immunomonitoring data in large molecule

November 10, 2022

Poster presentation SITC Annual Meeting 2022, Boston

Generation of a Highly Potent, Cis-signaling PD1-IL2 Immunocytokine Using a Novel Chemical Synthesis and Conjugation Platform

November 10, 2022

Poster presentation SITC Annual Meeting 2022, Boston

Using Site-Specific Chemical Conjugation to Generate Superior Half-Life Extended or PD1-Targeted Formats of a Potent IL-18 Variant Resistant to IL-18 Binding Protein

October 21, 2022

Poster presentation 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments Identification of BPT323

Identification of BPT323 – An immunocytokine for treatment of autoimmune diseases combining orthogonal modes of action of TNFα blockade and selective T_reg expansion

October 21, 2022

Poster presentation 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments

Identification of BPT264 – A potent alpha-enhanced/beta-dead and half-life-extended IL-2 T_reg enhancer for treatment of autoimmune diseases

April 13, 2022

Poster presentation AACR Annual Meeting 2022, New Orleans

Cis-activation of PD-1⁺ effector T cells with dual-targeting immunocytokines generated using a novel chemical conjugation platform. AACR Annual Meeting 2022, New Orleans

April 13, 2022

Poster presentation AACR Annual Meeting 2022, New Orleans

BPT-143: A fully synthetic alpha-dead IL-2 with a best-in-class preclinical pharmacodynamic and efficacy profile supporting first-in-human clinical development. AACR Annual Meeting 2022, New Orleans